Anuja Anil Mandavkar, Suraj Sai Nikhil Padakanti, Srajan Gupta, Samiyah Akram, Nida Jaffar, Jugalkishor Chauhan, Likhita Reddy Allu, Pulkit Saini, Jamil Nasrallah, Mohamed Abdullahi Omar, Muna Ali Mugibel, Saif Syed, Kumaran Ottilingam Ravindran, Ayush Dwivedi, Gurneet Singh Dhingra, Avleen Dhingra, Jay Kakadiya, Jana Kotaich, Shreya Singh Beniwal
{"title":"多发性骨髓瘤的新疗法：利用免疫检查点抑制剂改善预后。","authors":"Anuja Anil Mandavkar, Suraj Sai Nikhil Padakanti, Srajan Gupta, Samiyah Akram, Nida Jaffar, Jugalkishor Chauhan, Likhita Reddy Allu, Pulkit Saini, Jamil Nasrallah, Mohamed Abdullahi Omar, Muna Ali Mugibel, Saif Syed, Kumaran Ottilingam Ravindran, Ayush Dwivedi, Gurneet Singh Dhingra, Avleen Dhingra, Jay Kakadiya, Jana Kotaich, Shreya Singh Beniwal","doi":"10.1177/10932607241301699","DOIUrl":null,"url":null,"abstract":"<p><strong>Background:: </strong>Multiple Myeloma is a hematological malignancy characterized by the proliferation of clonal plasma cells and associated with severe clinical manifestations. Despite advancements in diagnosis and management, Multiple Myeloma remains incurable, necessitating further research into more effective therapies.</p><p><strong>Aim:: </strong>The primary objective of this review is to provide an informative and critical summary of the Multiple Myeloma microenvironment, and emerging revolutionary therapeutic approaches with potential combination therapy to improve the quality of life for Multiple Myeloma patients.</p><p><strong>Emerging approaches:: </strong>Recent advancements in immunotherapy, particularly immune checkpoint inhibitors (ICIs), have shown improvements in immune response against Multiple Myeloma. ICIs target inhibitory pathways such as PD-1/PD-L1 and CTLA-4, potentially overcoming tumor-induced immunosuppression. Combination therapies integrate ICIs with proteasome inhibitors, immunomodulators, and monoclonal antibodies to enhance the anti-tumor immune response. Additionally, Chimeric Antigen Receptor T-cell (CAR-T) therapy has demonstrated effectiveness against Multiple Myeloma, particularly when coupled with ICIs to decrease resistance and relapse.</p><p><strong>Challenges:: </strong>Although the efficacy of ICIs in treating Multiple Myeloma has been hindered by the complexity of the tumor microenvironment and immune evasion mechanisms, this challenge has led to the exploration of combination therapies. Potential side effects are still a big challenge for newly recognized ICIs and combination treatment.</p><p><strong>Future directions:: </strong>Investigations of new immune checkpoints and the development of targeted therapies against these markers are in progress, creating possibilities for more personalized and effective treatment strategies. Continuous research and robust clinical trials are needed to comprehend the complex dynamics of the Multiple Myeloma microenvironment to develop revolutionary therapeutic targets.</p>","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":" ","pages":"10932607241301699"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Emerging therapies in Multiple Myeloma: Leveraging immune checkpoint inhibitors for improved outcomes.\",\"authors\":\"Anuja Anil Mandavkar, Suraj Sai Nikhil Padakanti, Srajan Gupta, Samiyah Akram, Nida Jaffar, Jugalkishor Chauhan, Likhita Reddy Allu, Pulkit Saini, Jamil Nasrallah, Mohamed Abdullahi Omar, Muna Ali Mugibel, Saif Syed, Kumaran Ottilingam Ravindran, Ayush Dwivedi, Gurneet Singh Dhingra, Avleen Dhingra, Jay Kakadiya, Jana Kotaich, Shreya Singh Beniwal\",\"doi\":\"10.1177/10932607241301699\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background:: </strong>Multiple Myeloma is a hematological malignancy characterized by the proliferation of clonal plasma cells and associated with severe clinical manifestations. Despite advancements in diagnosis and management, Multiple Myeloma remains incurable, necessitating further research into more effective therapies.</p><p><strong>Aim:: </strong>The primary objective of this review is to provide an informative and critical summary of the Multiple Myeloma microenvironment, and emerging revolutionary therapeutic approaches with potential combination therapy to improve the quality of life for Multiple Myeloma patients.</p><p><strong>Emerging approaches:: </strong>Recent advancements in immunotherapy, particularly immune checkpoint inhibitors (ICIs), have shown improvements in immune response against Multiple Myeloma. ICIs target inhibitory pathways such as PD-1/PD-L1 and CTLA-4, potentially overcoming tumor-induced immunosuppression. Combination therapies integrate ICIs with proteasome inhibitors, immunomodulators, and monoclonal antibodies to enhance the anti-tumor immune response. Additionally, Chimeric Antigen Receptor T-cell (CAR-T) therapy has demonstrated effectiveness against Multiple Myeloma, particularly when coupled with ICIs to decrease resistance and relapse.</p><p><strong>Challenges:: </strong>Although the efficacy of ICIs in treating Multiple Myeloma has been hindered by the complexity of the tumor microenvironment and immune evasion mechanisms, this challenge has led to the exploration of combination therapies. Potential side effects are still a big challenge for newly recognized ICIs and combination treatment.</p><p><strong>Future directions:: </strong>Investigations of new immune checkpoints and the development of targeted therapies against these markers are in progress, creating possibilities for more personalized and effective treatment strategies. Continuous research and robust clinical trials are needed to comprehend the complex dynamics of the Multiple Myeloma microenvironment to develop revolutionary therapeutic targets.</p>\",\"PeriodicalId\":53564,\"journal\":{\"name\":\"Human Antibodies\",\"volume\":\" \",\"pages\":\"10932607241301699\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-01-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Antibodies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/10932607241301699\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Antibodies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/10932607241301699","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Emerging therapies in Multiple Myeloma: Leveraging immune checkpoint inhibitors for improved outcomes.
Background:: Multiple Myeloma is a hematological malignancy characterized by the proliferation of clonal plasma cells and associated with severe clinical manifestations. Despite advancements in diagnosis and management, Multiple Myeloma remains incurable, necessitating further research into more effective therapies.
Aim:: The primary objective of this review is to provide an informative and critical summary of the Multiple Myeloma microenvironment, and emerging revolutionary therapeutic approaches with potential combination therapy to improve the quality of life for Multiple Myeloma patients.
Emerging approaches:: Recent advancements in immunotherapy, particularly immune checkpoint inhibitors (ICIs), have shown improvements in immune response against Multiple Myeloma. ICIs target inhibitory pathways such as PD-1/PD-L1 and CTLA-4, potentially overcoming tumor-induced immunosuppression. Combination therapies integrate ICIs with proteasome inhibitors, immunomodulators, and monoclonal antibodies to enhance the anti-tumor immune response. Additionally, Chimeric Antigen Receptor T-cell (CAR-T) therapy has demonstrated effectiveness against Multiple Myeloma, particularly when coupled with ICIs to decrease resistance and relapse.
Challenges:: Although the efficacy of ICIs in treating Multiple Myeloma has been hindered by the complexity of the tumor microenvironment and immune evasion mechanisms, this challenge has led to the exploration of combination therapies. Potential side effects are still a big challenge for newly recognized ICIs and combination treatment.
Future directions:: Investigations of new immune checkpoints and the development of targeted therapies against these markers are in progress, creating possibilities for more personalized and effective treatment strategies. Continuous research and robust clinical trials are needed to comprehend the complex dynamics of the Multiple Myeloma microenvironment to develop revolutionary therapeutic targets.
期刊介绍：
Human Antibodies is an international journal designed to bring together all aspects of human hybridomas and antibody technology under a single, cohesive theme. This includes fundamental research, applied science and clinical applications. Emphasis in the published articles is on antisera, monoclonal antibodies, fusion partners, EBV transformation, transfections, in vitro immunization, defined antigens, tissue reactivity, scale-up production, chimeric antibodies, autoimmunity, natural antibodies/immune response, anti-idiotypes, and hybridomas secreting interesting growth factors. Immunoregulatory molecules, including T cell hybridomas, will also be featured.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
